TRANSASIA BIOMEDICALS LTD
EXTENDS
A WARM WELCOME TO
ALL
DIGNITARIES & DELEGATES
Responding to the needs of Quality Blood Analysis
DOING BUSINESS IN INDIA
PRESENTATION
BY
Suresh Vazirani
Chairman and Managing Director
Transasia Bio-Medicals Ltd
Responding to the needs of Quality Blood Analysis
To cut a long list of Good Reasons short...
India - A Large fast growing free market democracy
Versatile, skilled human capital
Abundant resources
Robust legal & business support systems
Sound economic fundamentals
Steady economic reform regime
Healthy, vibrant financial sector
Responding to the needs of Quality Blood Analysis
SOME AMAZING NUMBERS.....
Economic & social indicators
Population (Mn) 1,065
National Income A
Gross Domestic Product (GDP) (US$ Bn) 652
Share in GDP
Agriculture (%) 24
Industry, Manufacturing,
Services (%) 76
Per Capita PPP-
(World’s 5th largest PPP Economy ) (US$) 2,880
Social sector indicators
Primary schools (%) 99
Adult literacy (%) 61
Health expenditure (Public) (% to GDP) 1.5
Key metros with high per capita income
Average Population Average Household Income
India has 35 cities with over one
(’000) (US$)
million population.
3082 4107
Responding to the needs of Quality Blood Analysis
Some More Facts about India
India Offers Large Manufacturing Capability spanning almost all areas
of manufacturing activities
Developed Banking System,Commercial Banking network of over
85,000 branches
Conducive Foreign Investment Environment that provides Freedom of
entry, Investment, Location, Choice of Technology, Import and Export
Stable democratic environment in over 50 years of independence
Of course we are the No. 1 in providing gray matter to the world in
form of software professionals
Responding to the needs of Quality Blood Analysis
Overview of Healthcare in India
Healthcare Overview
SIZE Healthcare delivery is one of the largest service-sector industries in India
Estimated revenue (FY
2005) US$30 billion - 5% of the GDP
Industry Growth Rate Over 12% p.a. in the past four years
Medical Tourists Growth From 10,000 in 2000-01 to over 100,000 in 2004-05
Structure Highly Fragmented
Private Healthcare
Revenue Over 63%
Many Indian hospitals have secured accreditation from the British Standards
Accreditation Institute and Joint Commission on Accreditation of Healthcare Organizations
NHS, UK has indicated India as a preferred destination for surgery
Investment Policy 100% FDI is permitted for all health related services under the automatic route
Infrastructure status accorded to hospitals
Lower tariffs and higher depreciation on medical equipment
Income-tax exemption for five years to hospitals in rural areas
Responding to the needs of Quality Blood Analysis
THE OPPORTUNITY
Healthcare delivery is one of the largest service-sector industries in India
OUTLOOK The industry is expected to grow at 15% p.a. to $60 billion by 2010
Medical tourism, a US$333million Industry is expected to become a $2 billion industry by 2010
Significant growth in healthcare BPO: Expected to become a $4.5 billion industry by 2008
POTENTIAL High growth domestic market arising from - Increasing health awareness
Growing Private Consumption Expenditure - Increased from 3.5% (1993-94) to 5.3% (2000-01).
Expected spend by 2012 – US$74 billion
Increasing penetration of Health insurance - 100% growth in Health Insurance in the last two years
High growth in medical tourism - Cost of advanced surgeries in India is about 10% of that in USA
Opportunities exist in multiple segments along the value chain
Service Providers: Curative and preventive in primary, secondary and tertiary care
Diagnostics Services: Imaging and pathology labs
Infrastructure: Hospitals, Diagnostic centres
Health Insurance: Only 30-40 million Indians have Health Insurance; expected to rise to 160 million by
2010.
Healthcare BPO: Medical billing, disease coding, forms processing and claims adjudication
Training: Large opportunity for training doctors, managers, nurses and technicians
Investment opportunity of over $25 billion in the next 5 years
Responding to the needs of Quality Blood Analysis
Market Overview - India
Medical Equipment Market
USD 1760 Million
IVD Market
USD 400 Million
Year 2005
Responding to the needs of Quality Blood Analysis
IVD Market in India
Segment %
Immunology 24%
Critical Care 7%
Haemetology 14%
BioChemistry 37%
Coagulation 3%
Urine Routine 6%
Segment wise Indian Diagnostic Market Microbiology 4%
Others 5%
%
Others
Microbiology Immunology
Critical Care
Urine Routine
Immunology Haemetology
Coagulation
BioChemistry
Critical Care Coagulation
BioChemistry Urine Routine
Haemetology
Microbiology
Others
Responding to the needs of Quality Blood Analysis
IVD Market in India-
The Major Players
No Company name
1 Transasia Bio-Medicals Ltd
2 Roche Diagnostics
3 J.Mitra
4 J&J
5 Tulip
6 Bayer
7 Beckman Coulter / Wipro
8 Bio Merieux
9 Trivitron
10 Span
Responding to the needs of Quality Blood Analysis
Regulatory Reforms
Move towards standardized healthcare systems across the country,
legislations has been introduced to make compulsory the Registration
of all health establishments
All registered establishments will be graded based on specified
Standards
Proposal by the Central Government to set up Indian Medical Devices
Regulatory Authority
Proposal to make accreditation by the National Accreditation Board
compulsory for Laboratories for the over 100 thousand laboratories
in India (currently only appx. 100 path labs have be accredited.
Responding to the needs of Quality Blood Analysis
Future Trends
Shift towards Corporatized Diagnostic/Medical Services
Impending regulatory reforms will see closure of many small
laboratories
Rapid expansion of market driven by –
Higher incidence of Lifestyle Diseases
Higher penetration of Insurance Cover
Growth in Income and enhanced health awareness
Increased Urbanization from 30% to over 50% by year 2025
will mean larger mass coming under ambit of quality healthcare
systems
Responding to the needs of Quality Blood Analysis
THE TRANSASIA STORY
Responding to the needs of Quality Blood Analysis
Mission Statement
We, at Transasia, believe our first responsibility is -
To the Doctors and Patients, Worldwide, in meeting their needs for
Reliable, Affordable and Innovative Medical Diagnostic Systems.
Responding to the needs of Quality Blood Analysis
A Holistic Approach towards the Health Care
Vision to deliver products and services that can
solve the healthcare problems of the people
in the region
“TRANSASIA,”
a venture meant to be a “part of the solution”
was founded by me in 1979 with Rs. 250,
the last Honorarium from MRA
….. And a Strong Conviction that
they would be led by the “INNER VOICE” .
Responding to the needs of Quality Blood Analysis
The Guiding philosophy
Gandhiji stated –
Find the right cause ….
And the resources would follow
Mehanat aur Buddhi Se Kamayabi Payenge
Bharat ko Safal Karenge Hum
“With Intelligence & Hard Work
We will find Success
And bring glory to our motherland”
Responding to the needs of Quality Blood Analysis
XL 300/600 – INDIA’S FIRST AUTOMATED BIOCHEMISTRY ANALYSER
Exports to more than 55 countries around the Globe
LEBANON CAMBODIA CZECH REPUBLIC HONG KONG
BENIN CHINA PORTUGAL GERMANY INDONESIA
MALAYSIA BANGLADESH COLOMBIA
MEXICO EGYP T GREECE PHILIPPINES ROMANIA RUSSIA
TAIWAN MALDIVES ERITREA
JAPAN
MAKING QUALITY BLOOD
DIAGNOSIS SYSTEM FOR THE HUNGARY
TANZANIA VENEZUELA
WORLD INDIA
SINGAPORE
QATAR
ITALY
THAILAND UAE
PAKISTAN
KOREA
TURKEY UK
IRAN
NIGERIA
FRANCE KENYA SAUDI ARABIA
SPAIN
COSTA RICA VIETENAM NETHERLANDS YEMEN OMAN IRELAND SLOVAKIA SRI LANKA
Transasia - A COMPANY WITH GLOBAL AMBITIONS
Responding to the needs of Quality Blood Analysis
Few Facts about Transasia
No.1 Diagnostic Company in India
Revenues in excess of Rs. 1250 million
(Target of Rs.2000million for year ended 31st March 2007)
Market Leader - more than 35% market share in Biochemistry
& 50 % in Hematology
Largest Installed base - >10000 Instruments in India
>1500 Instruments overseas
Largest Sales force (over 225 nos.) and the most competent
technical service team (95 nos.)
Only Asian company (outside Japan) that can develop &
manufacture entire range of Bio-chemistry Analyzers
State of the Art R&D facility – Over 65 engineers working to
design & develop a range of Analyzers.
Responding to the needs of Quality Blood Analysis
Awards and Accolades
Recipient of National R&D Award
Instituted by Ministry of Science & Technology, Government of India
Recipient of the Emerging India Award
Adjudged the “Most Promising SME” of the Country
(Instituted by CNBC- ICICI Bank)
Winner of National Quality Award
Winner of National Export Award
Responding to the needs of Quality Blood Analysis
Reversing the Flow of Technology
FROM INDIA TO JAPAN
No.1 In Japan No. 1 in India
Hand over of First
CHEMIX-800
A Fully Automated
Biochemistry
Analyzer
Developed &
Manufactured by
Transasia, India
for
Global Distribution
by Sysmex, Japan
Responding to the needs of Quality Blood Analysis
Transasia will contribute to enhancing life and
improvement in healthcare through diagnostic solutions
by providing appropriate and affordable products and
services of the highest quality and reliability
VALUE CREATION FOR CUSTOMERS, EMPLOYESS & SOCIETY
Responding to the needs of Quality Blood Analysis
Responding to the needs of Quality Blood Analysis